Over-the-Counter Access to Low Dose CBD

On December 2020, the Therapeutic Goods Administration (TGA) announced that it will approve low-dose CBD containing products, up to a maximum consumption of 150 mg/day, for use by adults, to be supplied over the counter by a pharmacist, without a prescription. The TGA's final decision came into effect on 1 February 2021.


The decision was made following an earlier TGA safety review of low dose CBD - which revealed that the known adverse events of CBD at low doses were not severe. The decision was made following extensive public consultation.


The over-the-counter products will only be sold by way of oral, oral mucosal and sublingual formulations, with market estimation for consumers seeing medication on shelves likely pushed to late 2021/2022.

Cann Pharmaceutical Australia
Level 1
The Realm
18 National Circuit
Barton ACT 2600
+61 2 6198 3253
info@cannpharmaceutical.com.au
  • LinkedIn
  • Facebook
  • Twitter
  • YouTube
Screen Shot 2021-02-08 at 3.34.34 pm cop
Screen Shot 2021-02-08 at 3.43.34 pm cop
The content on this website is not intended as a substitute for professional medical advice and/or as a recommendation and/or approval to use cannabis products, whether they are sold by the company or by another party.
© 2021 Cann Pharmaceutical Australia. All Rights Reserved.